Crossmark

REDD2-mediated inhibition of mTOR promotes dendrite retraction induced by axonal injury

Crossref DOI link: https://doi.org/10.1038/cdd.2014.149

Published Online: 2014-09-26

Published Print: 2015-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Morquette, B

Morquette, P

Agostinone, J

Feinstein, E

McKinney, R A

Kolta, A

Di Polo, A
License Information

Text and Data Mining valid from 2014-09-26
More Information

Article History

Received: 25 June 2014

Revised: 7 August 2014

Accepted: 18 August 2014

First Online: 26 September 2014

Competing interests

: BM, PM, JA, RAM, AK and ADP declare no conflict of interest. EF is Chief Scientific Officer at Quark Pharmaceuticals and owns company’s stock options.